Funding

SECTION I: ESTIMATION OF COSTS

1 Taking into account the rest of the cost evaluation please provide an overall estimation of the total costs for full deployment/production of the R & D result.
… in terms of IPR protection
36 000€
…in terms of product development
32 000€
…in terms of mass production
38 000€
… in terms of marketing
3 000€
2 Based on the above assessment as well as the marketing information please provide the correct estimation of the price for R&D product in correlation with costs
Year 1 Year 2 Year 3 Year 4 Year 5
Fixed costs 19 200€ 38 400€ 60 800€ 91 200€ 115 200€
Personnel 19 200€ 38 400€ 60 800€ 91 200€ 115 200€
Other running costs 4 800€ 9 600€ 15 200€ 22 800€ 14 400€
Marketing costs 4 800€ 9 600€ 15 200€ 22 800€ 43 200€
TOTAL EXPECTED COSTS 48 000€ 96 000€ 152 000€ 228 000€ 288 000€
Price per Unit 2000€ 2000€ 1900€ 1900€ 1800€
Type of Unit system
Number of Units 30 60 100 150 200
TOTAL Expected Revenues 60 000€ 120 000€ 190 000€ 285 000€ 360 000€
CASH FLOW REQUIRED (REVENUES-COSTS) 12 000€ 24 000€ 38 000€ 57 000€ 72 000€
TOTAL CAPITAL required for five years 812 000= 48 000€+96 000€+152 000€+228 000€+288 000€

SECTION 2: QUALITATIVE FACTORS

4 Dimension of identified target groups
European funding – 80%

National funding  – 20%

6 Evaluation of financial Risks for R&D result
There are enough scientific investigations on magneto-therapy, enough positive results of testing of systems for magneto-therapy in real conditions in hospital and therefore in fact there are not any risks for R&D results.

SECTION 3: IDENTIFICATION OF FINANCING SOURCES

1. European Funding

Define relevance of the product with the following potential funding sources and comment

1.

2.

3.

4.

2 National Funding
1.

2.

3.

3 Private funding
1.

2.

3.

4 Other

SECTION 3: FINAL EVALUATION

It is requested a final evaluation considering the funding opportunities you believe most suitable for the exploitation of the R&D result, considering the possibility of the creation of a spin-off, further research, in particular, a cost/benefit analysis and a financial projection for the R&D result, type of collaboration identified (i.e. Licensing Agreement, Technical Cooperation, Joint Venture, Manufacturing Agreement, Commercial Agreement with Technical Assistance, Creation of a spin-off, Joint further development)…
The most suitable funding opportunities for exploitation of R&D results is European funding.

Decision of evaluation (Please tick  as appropriate)

The R&D has a high potential of exploitation

Bookmark the permalink. Follow any comments here with the RSS feed for this post. Post a comment or leave a trackback: Trackback URL.

Post a Comment

You must be logged in to post a comment.

Request a proposal

Valorisation Plan Authors

Related Documents

There in no related documents

Visit the other applications of the INTERVALUE Platform: R&D Repository | IP Agreements

© 2009-2010 INTERVALUE Project